These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18496219)

  • 1. Pharmacogenetic testing: not as simple as it seems.
    Haga SB; Burke W
    Genet Med; 2008 Jun; 10(6):391-5. PubMed ID: 18496219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics: ethical issues and policy options.
    Buchanan A; Califano A; Kahn J; McPherson E; Robertson J; Brody B
    Kennedy Inst Ethics J; 2002 Mar; 12(1):1-15. PubMed ID: 12211263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Providing patients with information on pharmacogenetic testing.
    Fleeman N; Dickson R
    Nurs Stand; 2009 Jan 28-Feb 3; 23(21):46-8. PubMed ID: 19248450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consent and privacy in pharmacogenetic testing.
    Robertson JA
    Nat Genet; 2001 Jul; 28(3):207-9. PubMed ID: 11431685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic testing, informed consent and the problem of secondary information.
    Netzer C; Biller-Andorno N
    Bioethics; 2004 Aug; 18(4):344-60. PubMed ID: 15449406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ancillary risk information and pharmacogenetic tests: social and policy implications.
    Henrikson NB; Burke W; Veenstra DL
    Pharmacogenomics J; 2008 Apr; 8(2):85-9. PubMed ID: 17486108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protecting communities in pharmacogenetic and pharmacogenomic research.
    Weijer C; Miller PB
    Pharmacogenomics J; 2004; 4(1):9-16. PubMed ID: 14647406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacogenetics in future medical care -- implications for patients and physicians].
    Rogausch A; Brockmöller J; Himmel W
    Gesundheitswesen; 2005 Apr; 67(4):257-63. PubMed ID: 15856385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 "early adopting" departments of psychiatry.
    Hoop JG; Lapid MI; Paulson RM; Roberts LW
    J Clin Psychiatry; 2010 Jun; 71(6):745-53. PubMed ID: 20361898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.
    J Clin Oncol; 1996 May; 14(5):1730-6; discussion 1737-40. PubMed ID: 8622094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient care.
    Thompson C; Steven P Hamilton ; Catriona Hippman
    Psychiatry Res; 2015 Mar; 226(1):68-72. PubMed ID: 25618469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attitudes of health care professionals toward pharmacogenetic testing.
    Zgheib NK; Arawi T; Mahfouz RA; Sabra R
    Mol Diagn Ther; 2011 Apr; 15(2):115-22. PubMed ID: 21623646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ethics, politics, and rights in pharmacogenomics].
    Bellver Capella V
    Rev Derecho Genoma Hum; 2002; (17):31-55. PubMed ID: 12703107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.
    Mills R; Haga SB
    Pharmacogenomics; 2013 Jun; 14(8):957-68. PubMed ID: 23746189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related direct-to-consumer genetic testing: a review of companies' policies with regard to genetic testing in minors.
    Borry P; Howard HC; Sénécal K; Avard D
    Fam Cancer; 2010 Mar; 9(1):51-9. PubMed ID: 19488835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legal and ethical issues in genetic testing and counseling for susceptibility to breast, ovarian and colon cancer.
    Dickens BM; Pei N; Taylor KM
    CMAJ; 1996 Mar; 154(6):813-8. PubMed ID: 8634959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer genetic susceptibility testing: ethical and policy implications for future research and clinical practice. Cancer Genetic Studies Consortium, National Institutes of Health.
    Wilfond BS; Rothenberg KH; Thomson EJ; Lerman C
    J Law Med Ethics; 1997; 25(4):243-51, 230. PubMed ID: 11066506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics in clinical practice: considerations for testing.
    Constable S; Johnson MR; Pirmohamed M
    Expert Rev Mol Diagn; 2006 Mar; 6(2):193-205. PubMed ID: 16512779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics: the bioethical problem of DNA investment banking.
    Corrigan OP; Williams-Jones B
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):550-65. PubMed ID: 16980194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.